News | Cath Lab | November 10, 2016

Study Concludes Very Early Percutaneous Coronary Intervention Following Fibrinolysis Safe

The Minneapolis Heart Institute Foundation conducted a 13-year study to determine the safety and feasibility of using PCI earlier in STEMI patients

fibrinolysis, FL, STEMI patients, ACCF/AHA guidelines, Minneapolis Heart Institute, AHA Scientific Sessions 2016

November 10, 2016 — Current ACCF/AHA guidelines recommend fibrinolysis (FL) as the preferred reperfusion strategy for ST-segment elevation myocardial infarction (STEMI) patients with expected delays of > 120 minutes from first medical contact to percutaneous coronary intervention (PCI). The guidelines recommend this be followed by transfer to a PCI center with angiography/PCI within 3-24 hours. However, assessment of reperfusion prior to angiography may not be accurate based on clinical and electrocardiogram (ECG) criteria alone. Recent data suggested increased recurrent ischemic events within the first 24 hours. The aim of this study, which was conducted from 2003-2015, was to assess the safety of very early PCI (< 3 hours) following FL.

The Minneapolis Heart Institute Level 1 MI program is a regional STEMI system with a standardized protocol where patients transferred from spoke hospitals with expected delays of > 120 minutes to PCI receive a pharmacoinvasive (PI) therapy with transfer for immediate PCI. Prospective registry data from the Level 1 database were analyzed to compare clinical outcomes related to the timing of PCI following FL, stratified into groups of <60, 61-90, 91-120, 121-180 and >180 minutes. Patients transferred for PCI alone were available for comparison.

From 2003 to 2015, 3,453 STEMI patients were transferred from spoke hospitals for immediate PCI, including 867 receiving FL. Pre-PCI IMI 2/3 flow occurred in 71 percent, but decreased with longer time from FL to PCI. The majority of PI patients underwent PCI 61-90 (47 percent) or 91-120 (28 percent) minutes post-FL. There were no significant differences in mortality, bleeding, reinfarction or stroke related to timing of PCI between these five groups. These results indicate that early PCI (< 3 hours) after FL is safe and may decrease recurrent ischemia. Therefore, delaying PCI for 3-24 hours following FL may not be necessary.

A poster presentation on the study will be given at the American Heart Association Scientific Sessions, Nov. 12-16, in New Orleans.

For more information: www.mplsheart.org

Related Content

Teleflex Launches Next-Generation Sympro Elite and Expro Elite Snares
Technology | Cath Lab | February 07, 2018
Teleflex Inc. has announced 510(k) clearance by the U.S. Food and Drug Administration (FDA) and U.S. commercial launch...
SCAI Advocacy Committee Highlights Reimbursement Reform Efforts in 2017
News | Cath Lab | January 30, 2018
The Society for Cardiovascular Angiography and Interventions (SCAI) highlighted the efforts of its Advocacy Committee...
IAC Releases Cardiovascular Catheterization Accreditation Program
News | Cath Lab | January 25, 2018
January 25, 2018 – The Intersocietal Accreditation Commission (IAC) announced the release of its Cardiovascular Cathe
Videos | Cath Lab | January 04, 2018
Bernadette Speiser, BSN, MSN, CCRN, RCIS, a cardiac cath/EP nurse at Palo Alto Veterans Hospital, Palo Alto, Calif.,
FDA Initiates Class I Recall of Sterilmed Reprocessed Agilis Steerable Introducer Sheath
News | Cath Lab | January 04, 2018
The U.S. Food and Drug Administration (FDA) announced a Class I recall of Sterilmed’s Agilis Steerable Introducer...
The California Heart & Vascular Clinic in El Centro, Calif., treated the first post-FDA clearance patient with a DABRA atherectomy system. Athar Ansari, M.D.

The California Heart & Vascular Clinic in El Centro, Calif., treated the first post-FDA clearance patient with a DABRA system. 

Feature | Cath Lab | November 24, 2017 | Athar Ansari, M.D., FACC
As debates about the current state and future of healthcare rage in Congress, the media and healthcare settings acros
Videos | Cath Lab | November 08, 2017
Juan Granada, M.D., Cardiovascular Research Foundation president and chief executive officer, shares his insights on
Results of the ORBITA study found no difference in exercise time after six weeks in patients with stable angina who received percutaneous coronary intervention (PCI) versus a placebo treatment. TCT 2017
Feature | Cath Lab | November 06, 2017
November 6, 2017 – Results from ORBITA, a prospective multi-center randomized blinded placebo-controlled study, found
Culprit Lesion-Only PCI Improves Outcomes for Cardiogenic Shock Patients Compared to Multivessel PCI
News | Cath Lab | November 01, 2017
November 1, 2017 — Results from the prospective, randomized, multicenter CULPRIT-SHOCK trial found an initial strateg
Overlay Init